G1 Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

Rhea-AI Summary

G1 Therapeutics, Inc. (GTHX) announced a webcast and conference call scheduled for May 3, 2023, at 8:30 a.m. ET, to provide a financial and corporate update for Q1 2023. The live event will discuss the company’s progress in developing COSELA® (trilaciclib), its first commercial product, and ongoing clinical trials across various solid tumors, including breast, lung, and bladder cancers. Participants are encouraged to register online to receive dial-in details, and a recorded version of the webcast will be available for 90 days post-event on the company's website. G1 Therapeutics continues to focus on advancing therapies that enhance patient outcomes in oncology.

RESEARCH TRIANGLE PARK, N.C., April 26, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a financial and corporate update for the first quarter 2023 on Wednesday May 3, 2023, at 8:30 a.m. ET.

Please note that there is a new process to access the call via telephone. To register and receive a dial in number and unique PIN to access the live conference call, please follow this link to register online. While not required, it is recommended that you join 10 minutes prior to the start of the event. A live and archived webcast will be available on the Events & Presentations page of the company’s website: www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA® (trilaciclib). G1 has a deep clinical pipeline and is executing a development plan evaluating COSELA in a variety of solid tumors, including breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

G1 Therapeutics® and the G1 Therapeutics logo and COSELA^® and the COSELA logo are trademarks of G1 Therapeutics, Inc.

G1 Therapeutics Contacts:

Will Roberts
Vice President
Investor Relations and Corporate Communications
(919) 907-1944
wroberts@g1therapeutics.com

FAQ

When is G1 Therapeutics' Q1 2023 financial update?

G1 Therapeutics' Q1 2023 financial update is scheduled for May 3, 2023, at 8:30 a.m. ET.

What product is G1 Therapeutics focusing on in its oncology pipeline?

G1 Therapeutics is focusing on COSELA® (trilaciclib) as its first commercial product in its oncology pipeline.

How can I access the G1 Therapeutics webcast?

You can access the G1 Therapeutics webcast by registering online to receive a dial-in number and unique PIN.

What types of cancers is G1 Therapeutics developing therapies for?

G1 Therapeutics is developing therapies for various solid tumors, including breast, lung, and bladder cancers.